Edwards Lifesciences (EW) Revenue (2009 - 2026)

Edwards Lifesciences has reported Revenue for 18 years, with the latest figure at $1.7 billion in Q2 2026.

• On a quarterly basis, Revenue rose 13.63% year-over-year to $1.7 billion in Q2 2026; TTM through Jun 2026 was $6.5 billion, a 14.55% increase from a year earlier, with the FY2025 full-year figure at $6.1 billion, up 11.55% from the prior year.
• Revenue was $1.7 billion for Q2 2026 at Edwards Lifesciences, up from $1.6 billion in the prior quarter.
• The five-year high for Revenue was $1.7 billion in Q2 2026, with the low at $429.9 million in Q4 2022.
• Average Revenue over 5 years is $1.4 billion, with a median of $1.4 billion recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Revenue tumbled 67.67% in 2022, then surged 194.58% in 2023.
• Over 5 years, Revenue stood at $429.9 million in 2022, then soared by 194.58% to $1.3 billion in 2023, then grew by 9.43% to $1.4 billion in 2024, then advanced by 13.26% to $1.6 billion in 2025, then increased by 10.92% to $1.7 billion in 2026.
• The last three Revenue figures came in at $1.7 billion (Q2 2026), $1.6 billion (Q1 2026), and $1.6 billion (Q4 2025), per Business Quant data.